BioCentury
ARTICLE | Politics & Policy

C-PATH consortium seeks to qualify diabetes biomarkers

March 21, 2017 9:59 PM UTC

The Critical Path Institute (Tucson, Ariz.) launched a consortium that will aim to qualify biomarkers for Type I diabetes with FDA and EMA.

The Leona M. and Harry B. Helmsley Charitable Trust, the Janssen Research & Development LLC unit of Johnson & Johnson (NYSE:JNJ), Juvenile Diabetes Research Foundation (JDRF) International and Sanofi (Euronext:SAN; NYSE:SNY) will fund the consortium...